The world’s population is rapidly aging, and we now increasingly face challenges related to the prevalence of age-related diseases. Studies from Geroscience have identified hallmarks of aging, such as the cellular senescence and mechanistic target of rapamycin (mTOR) pathways, that can be disrupted to improve health and lifespan in model organisms. Previous studies have shown that these pathways can be targeted pharmacologically by the mTOR inhibitor rapamycin or the senolytic drug combination Dasatinib + Quercetin (DQ). Our laboratory’s published data shows that rapamycin restored oral health in aged mice and reversed periodontal disease. While attempting to uncover the mechanism behind this reversal, our laboratory discovered that the age-related increase in cellular senescence was attenuated by rapamycin treatment. Thus, we hypothesized that targeting cellular senescence may provide an alternative therapeutic strategy to phenocopy the impact of rapamycin on aging oral tissues. I compared the effects of control (n=5), rapamycin (n=5), and the senolytic drug combination, DQ (n=5), in aged male mice (20-21 months old). Western Blot was performed on the mandible and salivary gland tissues to analyze the senescence marker p16INK4a. Histological assessment of H&E and lipofuscin staining was completed on the salivary glands to compare the effects of age, rapamycin, and DQ treatment. In male salivary glands, I discovered the age-related increase in p16 expression was decreased after rapamycin treatment, but not with DQ treatment. There were no significant changes in levels of p16 in the mandible with age or with the administration of rapamycin or DQ. Rapamycin treatment attenuated cellular senescence in male salivary glands, while the senolytic cocktail DQ had no impact on the aging male salivary glands. Future studies could be performed on female mice, with the addition of alternative senolytics which may target other markers of cellular senescence beyond p16.